Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting
PITTSBURGH, April 04, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new preclinical data on local and systemic immune activation following intratumoral injection of the Company’s platform technology encoding murine interleukin-12 (IL-12) and interleukin-2 (IL-2), the species matched equivalent to the Company’s clinical-stage oncology product candidate KB707, at the American Association for Cancer Research (AACR) 2024 Annual Meeting being held from April 5-10, 2024 in San Diego, California.
- PITTSBURGH, April 04, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new preclinical data on local and systemic immune activation following intratumoral injection of the Company’s platform technology encoding murine interleukin-12 (IL-12) and interleukin-2 (IL-2), the species matched equivalent to the Company’s clinical-stage oncology product candidate KB707, at the American Association for Cancer Research (AACR) 2024 Annual Meeting being held from April 5-10, 2024 in San Diego, California.
- Poster presentation details are as follows:
The poster will be available to conference attendees. - Following the presentation, the poster will also be available to view online on the Investor section of the Company’s website .